PEP/NEWS — Peptide intel. Daily.

RETATRUTIDE (GLP-3 TRIPLE AGONIST) SHOWED ~24% BODY WEIGHT REDUCTION IN PHASE 2 TRIALEPITALON HAS BEEN STUDIED IN HUMAN TRIALS SINCE THE 1980S UNDER RESEARCHER VLADIMIR KHAVINSONTB-500 (THYMOSIN BETA-4) BINDS G-ACTIN AT A 1:1 MOLAR RATIO — CORE TO ITS REPAIR MECHANISMPAI-1 LOSS-OF-FUNCTION MUTATION IN HUMANS ASSOCIATED WITH UP TO 7 EXTRA YEARS OF LIFETIME-RESTRICTED FEEDING EXTENDED MALE MOUSE LIFESPAN IN NEW NATURE AGING CONTROLLED STUDYGHK-CU (COPPER PEPTIDE) UPREGULATES OVER 30 GENES INVOLVED IN TISSUE REPAIR PER PUBLISHED DATASEMAGLUTIDE REDUCES CARDIOVASCULAR EVENTS BY ~20% IN HIGH-RISK PATIENTS PER SELECT TRIAL DATALOW-DOSE RAPAMYCIN USERS NOW NUMBER IN THE TENS OF THOUSANDS GLOBALLY WITH NO LARGE RCT YET COMPLETE RETATRUTIDE (GLP-3 TRIPLE AGONIST) SHOWED ~24% BODY WEIGHT REDUCTION IN PHASE 2 TRIALEPITALON HAS BEEN STUDIED IN HUMAN TRIALS SINCE THE 1980S UNDER RESEARCHER VLADIMIR KHAVINSONTB-500 (THYMOSIN BETA-4) BINDS G-ACTIN AT A 1:1 MOLAR RATIO — CORE TO ITS REPAIR MECHANISMPAI-1 LOSS-OF-FUNCTION MUTATION IN HUMANS ASSOCIATED WITH UP TO 7 EXTRA YEARS OF LIFETIME-RESTRICTED FEEDING EXTENDED MALE MOUSE LIFESPAN IN NEW NATURE AGING CONTROLLED STUDYGHK-CU (COPPER PEPTIDE) UPREGULATES OVER 30 GENES INVOLVED IN TISSUE REPAIR PER PUBLISHED DATASEMAGLUTIDE REDUCES CARDIOVASCULAR EVENTS BY ~20% IN HIGH-RISK PATIENTS PER SELECT TRIAL DATALOW-DOSE RAPAMYCIN USERS NOW NUMBER IN THE TENS OF THOUSANDS GLOBALLY WITH NO LARGE RCT YET COMPLETE

Last updated June 9, 2026 — I read this morning's peptide research and picked the items that mattered. Fresh brief tomorrow.

◤ Top story · Nature Briefing
WORLD-FIRST CELLULAR REJUVENATION THERAPY ADMINISTERED TO A HUMAN PATIENT...

*A therapy designed to make cells biologically younger has been given to a person for the first time.*

— Nature Briefing

Featured Briefs

◤ From the network · Research Vials

PEPTIDE RESEARCH TRENDS TO WATCH IN 2026

The five biggest trends shaping peptide research in 2026 — from GLP-1 agonist evolution to mitochondrial peptides, AI-driven discovery, and the post-Peptide Sciences landscape.

Research Vials
◤ Article · Peptide-anchored

AOD-9604 VS SEMAGLUTIDE: METABOLIC RESEARCH COMPARED SIDE BY SIDE...

AOD-9604 (a GH fragment studied for fat metabolism) and Semaglutide (a GLP-1 receptor agonist) target metabolic function through very different pathways. This comparison examines what the published research actually shows for each.

Research Vials
▶ Video

WHAT IS SLU-PP-332?

Curious about the growing interest in SLU-PP-332 and its potential effects on fat loss, endurance, and metabolic health? In this video, I explain what SLU-PP-332 is, how it works as an exercise-mimetic compound, and the science behind its i

Regan Archibald
▶ Video

SLU-PP-332 BODYBUILDING?

Struggling to improve endurance, recovery, and fat loss without sacrificing muscle mass? In this video, I break down how SLU-PP-332 may support mitochondrial health, increase oxidative capacity, and help bodybuilders and athletes build a st

Regan Archibald

More Headlines